The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.
- Study Type: Observational
- Study Design
- Time Perspective: Other
- Study Primary Completion Date: June 30, 2023
This is a cohort study in patients with ischemic stroke. The demographic characteristics, TCM syndromes, and other baseline information will be recorded. At the same time, baseline peripheral blood will be collected. These participants will be followed up to 90 days of onset, and 90-day modified Rankin scale (mRS) scores will be assessed. The collected blood samples will be tested by multi-factor detection technology for candidate biomarkers.
Arms, Groups and Cohorts
- Phlegm-heat syndrome in ischemic stroke
- Phlegm-heat syndrome: the score of “Phlegm-dampness syndrome” ≥10 with the score of “Internal fire syndrome” ≥10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke
- Non-phlegm-heat syndrome in ischemic stroke
- Non-phlegm-heat syndrome: the score of “Phlegm-dampness syndrome” <10 with the score of “Internal fire syndrome” <10 in Diagnostic Scale for Syndrome Elements of Ischemic Stroke
- Healthy subjects
Clinical Trial Outcome Measures
- Omic biomarkers associated with phelm-heat syndrome in ischemic stroke
- Time Frame: baseline
- Sensitivity, specificity, and area under the ROC curve of omic biomarkers of Phlegm-heat syndrome in ischemic stroke.
Participating in This Clinical Trial
- Acute ischemic stroke, were confirmed by magnetic resonance imaging (MRI). – Symptom onset within 72 hours. – Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome. – Male or female ≥ 50 years and ≤ 80 years. – With written informed consent. Exclusion Criteria:
- Planned or already receiving intravenous thrombolysis or endovascular treatment. – Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment. – Patients with previous stroke. – Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases. – Other conditions that may affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).
Gender Eligibility: All
Minimum Age: 50 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Dongzhimen Hospital, Beijing
- Provider of Information About this Clinical Study
- Principal Investigator: Ying Gao, Professor – Dongzhimen Hospital, Beijing
- Overall Contact(s)
- Xinxing Lai, 8615901111280, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.